A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Clinical trial NCT03194893 · COMPLETED
Trial details
- NCT number
- NCT03194893
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-07-05
- Primary completion
- 2025-09-18
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.